Cargando…
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
PURPOSE: Sensitivity to a tyrosine kinase inhibitor (TKI) is correlated with the presence of somatic mutations that affect the kinase domain of epidermal growth factor receptor (EGFR). Development of resistance to TKI is a major therapeutic problem in non-small cell lung cancer (NSCLC). Aim of this...
Autores principales: | Sudo, Makoto, Chin, Tan Min, Mori, Seiichi, Doan, Ngan B., Said, Jonathan W., Akashi, Makoto, Koeffler, H. Phillip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636434/ https://www.ncbi.nlm.nih.gov/pubmed/23515752 http://dx.doi.org/10.1007/s00280-013-2132-y |
Ejemplares similares
-
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2014) -
SOX7 is down-regulated in lung cancer
por: Hayano, Takahide, et al.
Publicado: (2013) -
ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018) -
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer
por: Kaneto, Naoki, et al.
Publicado: (2014) -
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
por: Sun, Cuilan, et al.
Publicado: (2020)